EFPIA Wants Continued And More Inclusive Japan Policy Dialog
The European research-based pharma industry in Japan continues to call for a pricing system that better encourages innovation and for inclusive discussions on reforms that address health system challenges and focus on patients.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.